MD4624B1 - Virusuri oncolitice de vaccin variolic şi terapii imunooncolitice - Google Patents
Virusuri oncolitice de vaccin variolic şi terapii imunooncolitice Download PDFInfo
- Publication number
- MD4624B1 MD4624B1 MDA20160027A MD20160027A MD4624B1 MD 4624 B1 MD4624 B1 MD 4624B1 MD A20160027 A MDA20160027 A MD A20160027A MD 20160027 A MD20160027 A MD 20160027A MD 4624 B1 MD4624 B1 MD 4624B1
- Authority
- MD
- Moldova
- Prior art keywords
- oncolytic
- immuno
- vaccinia viruses
- therapies
- viruses
- Prior art date
Links
- 241000700618 Vaccinia virus Species 0.000 title abstract 3
- 230000000174 oncolytic effect Effects 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 101000595548 Homo sapiens TIR domain-containing adapter molecule 1 Proteins 0.000 abstract 1
- 102000003996 Interferon-beta Human genes 0.000 abstract 1
- 108090000467 Interferon-beta Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100036073 TIR domain-containing adapter molecule 1 Human genes 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000005809 anti-tumor immunity Effects 0.000 abstract 1
- 230000005875 antibody response Effects 0.000 abstract 1
- 230000007236 host immunity Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 229960001388 interferon-beta Drugs 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 244000309459 oncolytic virus Species 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Invenţia se referă la virusuri oncolitice de vaccin variolic, modificate pentru a stimula imunitatea antitumorală şi/sau a diminua imunitatea gazdei şi/sau răspunsul anticorpilor gazdei împotriva virusului.Esenţa invenţiei constă în aceea, că virusul oncolitic de vaccin variolic conţine un acid nucleic, care codifică domeniul Toll/IL-1R cu conţinut de proteină adaptoare, care induce interferon beta (TRIF) sau un domeniu funcţional al acesteia. De asemenea invenţia se referă la metode de utilizare a virusurilor oncolitice în tratamentul tumorilor maligne.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361868978P | 2013-08-22 | 2013-08-22 | |
| PCT/US2014/052308 WO2015027163A1 (en) | 2013-08-22 | 2014-08-22 | Immuno-oncolytic therapies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| MD20160027A2 MD20160027A2 (ro) | 2016-08-31 |
| MD4624B1 true MD4624B1 (ro) | 2019-03-31 |
| MD4624C1 MD4624C1 (ro) | 2019-10-31 |
Family
ID=52484194
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MD20160027A MD4624C1 (ro) | 2013-08-22 | 2014-08-22 | Virusuri oncolitice de vaccin variolic şi terapii imunooncolitice |
| MDA20180086A MD4748C1 (ro) | 2013-08-22 | 2014-08-22 | Terapii imunooncolitice |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20180086A MD4748C1 (ro) | 2013-08-22 | 2014-08-22 | Terapii imunooncolitice |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US11478518B2 (ro) |
| EP (3) | EP4324918A3 (ro) |
| JP (3) | JP6912199B2 (ro) |
| KR (1) | KR102389240B1 (ro) |
| CN (1) | CN105658795B (ro) |
| AU (1) | AU2014308648B2 (ro) |
| CA (3) | CA3213715A1 (ro) |
| DK (2) | DK3778897T3 (ro) |
| EA (1) | EA037582B1 (ro) |
| ES (2) | ES2847305T3 (ro) |
| FI (1) | FI3778897T3 (ro) |
| HR (1) | HRP20240078T1 (ro) |
| HU (1) | HUE066593T2 (ro) |
| IL (1) | IL243996A0 (ro) |
| LT (1) | LT3778897T (ro) |
| MD (2) | MD4624C1 (ro) |
| MX (1) | MX2016002257A (ro) |
| NZ (1) | NZ716825A (ro) |
| PE (1) | PE20160673A1 (ro) |
| PH (1) | PH12016500329A1 (ro) |
| PL (1) | PL3778897T3 (ro) |
| PT (1) | PT3778897T (ro) |
| RS (1) | RS65104B1 (ro) |
| SG (1) | SG11201600960PA (ro) |
| SI (1) | SI3778897T1 (ro) |
| SM (1) | SMT202400047T1 (ro) |
| WO (1) | WO2015027163A1 (ro) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202400047T1 (it) * | 2013-08-22 | 2024-03-13 | Univ Pittsburgh Commonwealth Sys Higher Education | Terapie immuno-oncolitiche |
| WO2016144564A2 (en) | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| CN107847534B (zh) | 2015-04-17 | 2022-10-04 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
| US10370647B2 (en) * | 2015-07-22 | 2019-08-06 | National University Corporation Tottori University | Host regulatory factor that enhances replication and/or propagation of vaccinia virus |
| WO2017043815A1 (en) * | 2015-09-08 | 2017-03-16 | Sillajen, Inc. | Modified oncolytic vaccinia viruses expressing a cytokine and a car- boxylesterase and methods of use thereof |
| CN108884159A (zh) | 2015-11-07 | 2018-11-23 | 茂体外尔公司 | 用于癌症治疗的包含肿瘤抑制基因治疗和免疫检查点阻断的组合物 |
| SG11201807051VA (en) | 2016-02-25 | 2018-09-27 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy |
| IL261321B2 (en) | 2016-02-25 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors |
| WO2017165725A1 (en) * | 2016-03-25 | 2017-09-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Synthetically enveloped virus |
| EP3254692A1 (en) * | 2016-06-10 | 2017-12-13 | Ceva Sante Animale | Multivalent recombinant spv |
| KR102619496B1 (ko) | 2016-07-19 | 2023-12-29 | 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | Stat3를 타겟으로 하는 종양용해성 바이러스 |
| JP2019528753A (ja) * | 2016-09-21 | 2019-10-17 | スティーブン エイチ． ソーン， | 高移動度グループｂｏｘｉ突然変異体 |
| GB201616365D0 (en) | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
| EP3551226A1 (en) | 2016-12-12 | 2019-10-16 | MultiVir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| KR20190128050A (ko) * | 2017-02-03 | 2019-11-14 | 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 종양용해성 바이러스 요법 |
| WO2018165161A1 (en) * | 2017-03-06 | 2018-09-13 | Novartis Ag | Methods and compositions for determining the potency of a therapeutic cellular composition |
| JP7718815B2 (ja) * | 2017-04-21 | 2025-08-05 | シルラゼン， インコーポレイテッド | 腫瘍溶解性ワクシニアウイルスおよびチェックポイント阻害剤の併用療法 |
| WO2018209315A1 (en) | 2017-05-12 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| JP7551496B2 (ja) | 2017-10-31 | 2024-09-17 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 全身送達のためのプラットフォーム腫瘍溶解性ベクター |
| US11633441B2 (en) | 2017-12-01 | 2023-04-25 | Gerd Sutter | Immuno-modulated replication-efficient vaccinia virus strain |
| JP7312412B2 (ja) * | 2018-01-05 | 2023-07-21 | オタワ ホスピタル リサーチ インスティチュート | 改変オルトポックスウイルスベクター |
| AU2019322487B2 (en) | 2018-03-19 | 2024-04-18 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer |
| CN112739374A (zh) * | 2018-07-20 | 2021-04-30 | 安迅生物制药公司 | 唾液酸酶向癌细胞、免疫细胞和肿瘤微环境的递送 |
| CN116162654A (zh) | 2018-09-15 | 2023-05-26 | 纪念斯隆凯特琳癌症中心 | 用于癌症免疫疗法的重组痘病毒 |
| TW202039851A (zh) * | 2018-12-21 | 2020-11-01 | 美商特斯通生物技術公司 | 經修飾正痘病毒載體 |
| CA3125020A1 (en) * | 2019-01-07 | 2020-07-16 | Kalivir Immunotherapeutics, Inc. | Methods of treating cancer |
| TW202038994A (zh) * | 2019-01-14 | 2020-11-01 | 美商醫格耐免疫治療公司 | 重組痘瘡病毒及其使用方法 |
| CA3129883A1 (en) * | 2019-02-14 | 2020-08-20 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| CN114340649A (zh) * | 2019-08-26 | 2022-04-12 | 拜耳诺克斯有限公司 | 包含痘苗病毒和羟基脲作为活性成分的用于治疗癌症的药物组合物 |
| KR20220082025A (ko) * | 2019-10-16 | 2022-06-16 | 칼리버 임뮤노쎄라퓨틱스, 인크. | 변형된 세포외 외피보유 바이러스 |
| EP4061417A4 (en) * | 2019-11-20 | 2023-10-11 | University of Pittsburgh - of the Commonwealth System of Higher Education | VACCINIA VIRUSES AND METHOD FOR USING VACCINIA VIRUSES |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| WO2021116943A1 (en) * | 2019-12-12 | 2021-06-17 | Ignite Immunotherapy, Inc. | Variant oncolytic vaccinia virus and methods of use thereof |
| BR112022013521A2 (pt) * | 2020-01-09 | 2022-09-13 | Pfizer | Vírus vaccinia recombinante |
| JP2023517183A (ja) * | 2020-03-06 | 2023-04-24 | ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | がんを治療するためのｉｒｆモジュレーター発現腫瘍溶解性ウィルス |
| WO2022109133A1 (en) | 2020-11-19 | 2022-05-27 | Kalivir Immunotherapeutics, Inc. | Oncolytic immunotherapy by tumor micro-environment remodeling |
| WO2022232375A1 (en) | 2021-04-30 | 2022-11-03 | Kalivir Immunotherapeutics, Inc. | Oncolytic viruses for modified mhc expression |
| KR20240026507A (ko) * | 2021-06-29 | 2024-02-28 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도 |
| WO2023106839A1 (ko) * | 2021-12-07 | 2023-06-15 | 재단법인 아산사회복지재단 | Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003258168B2 (en) * | 2002-08-12 | 2009-10-29 | Sillajen Biotherapeutics, Inc. | Methods and compositions concerning poxviruses and cancer |
| WO2007023725A1 (ja) * | 2005-08-25 | 2007-03-01 | Yokohama City University | 遺伝子ワクチン |
| US8980246B2 (en) * | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
| EP1933857A2 (en) * | 2005-09-07 | 2008-06-25 | Jennerex Biotherapeutics ULC | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
| AU2012244210B2 (en) * | 2005-09-07 | 2014-10-02 | Sillajen Biotherapeutics, Inc. | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
| KR20080084528A (ko) * | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| US20110038843A1 (en) * | 2008-03-31 | 2011-02-17 | Kusmartsev Sergei A | Tumor Growth Inhibition Via Conditioning of Tumor Microenvironment |
| EP2477499B1 (en) | 2009-09-14 | 2018-04-11 | SillaJen Biotherapeutics, Inc. | Oncolytic vaccinia virus combination cancer therapy |
| WO2011119925A2 (en) * | 2010-03-25 | 2011-09-29 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthetic herpes simplex viruses for treatment of cancers |
| WO2012142529A2 (en) * | 2011-04-15 | 2012-10-18 | Genelux Corporation | Clonal strains of attenuated vaccinia viruses and methods of use thereof |
| US20150250837A1 (en) * | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| SMT202400047T1 (it) | 2013-08-22 | 2024-03-13 | Univ Pittsburgh Commonwealth Sys Higher Education | Terapie immuno-oncolitiche |
-
2014
- 2014-08-22 SM SM20240047T patent/SMT202400047T1/it unknown
- 2014-08-22 JP JP2016536482A patent/JP6912199B2/ja active Active
- 2014-08-22 MX MX2016002257A patent/MX2016002257A/es unknown
- 2014-08-22 MD MD20160027A patent/MD4624C1/ro active IP Right Grant
- 2014-08-22 EP EP23215391.6A patent/EP4324918A3/en not_active Withdrawn
- 2014-08-22 EP EP20189155.3A patent/EP3778897B1/en active Active
- 2014-08-22 HR HRP20240078TT patent/HRP20240078T1/hr unknown
- 2014-08-22 SI SI201432060T patent/SI3778897T1/sl unknown
- 2014-08-22 CN CN201480058401.0A patent/CN105658795B/zh active Active
- 2014-08-22 EP EP14837931.6A patent/EP3036329B1/en active Active
- 2014-08-22 PL PL20189155.3T patent/PL3778897T3/pl unknown
- 2014-08-22 ES ES14837931T patent/ES2847305T3/es active Active
- 2014-08-22 HU HUE20189155A patent/HUE066593T2/hu unknown
- 2014-08-22 PE PE2016000287A patent/PE20160673A1/es unknown
- 2014-08-22 KR KR1020167006785A patent/KR102389240B1/ko active Active
- 2014-08-22 DK DK20189155.3T patent/DK3778897T3/da active
- 2014-08-22 SG SG11201600960PA patent/SG11201600960PA/en unknown
- 2014-08-22 EA EA201690444A patent/EA037582B1/ru unknown
- 2014-08-22 CA CA3213715A patent/CA3213715A1/en active Pending
- 2014-08-22 MD MDA20180086A patent/MD4748C1/ro active IP Right Grant
- 2014-08-22 WO PCT/US2014/052308 patent/WO2015027163A1/en not_active Ceased
- 2014-08-22 DK DK14837931.6T patent/DK3036329T3/da active
- 2014-08-22 FI FIEP20189155.3T patent/FI3778897T3/fi active
- 2014-08-22 RS RS20240082A patent/RS65104B1/sr unknown
- 2014-08-22 CA CA2921041A patent/CA2921041C/en active Active
- 2014-08-22 LT LTEP20189155.3T patent/LT3778897T/lt unknown
- 2014-08-22 ES ES20189155T patent/ES2971528T3/es active Active
- 2014-08-22 CA CA3213683A patent/CA3213683A1/en active Pending
- 2014-08-22 AU AU2014308648A patent/AU2014308648B2/en active Active
- 2014-08-22 NZ NZ716825A patent/NZ716825A/en unknown
- 2014-08-22 PT PT201891553T patent/PT3778897T/pt unknown
-
2016
- 2016-02-07 IL IL243996A patent/IL243996A0/en unknown
- 2016-02-18 PH PH12016500329A patent/PH12016500329A1/en unknown
- 2016-02-19 US US15/048,698 patent/US11478518B2/en active Active
-
2019
- 2019-07-19 JP JP2019133264A patent/JP7021154B2/ja active Active
-
2022
- 2022-02-03 JP JP2022015459A patent/JP7333431B2/ja active Active
- 2022-09-07 US US17/939,707 patent/US20230008089A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD4624B1 (ro) | Virusuri oncolitice de vaccin variolic şi terapii imunooncolitice | |
| EA201691631A1 (ru) | Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции | |
| CY1123563T1 (el) | Ανοσογονικα wt-1 πεπτιδια και μεθοδοι χρησης αυτων | |
| CY1124921T1 (el) | Μεθοδοι για την εκχυλιση και τον καθαρισμο μη μετουσιωμενων πρωτεϊνων | |
| CY1125387T1 (el) | Αντιγονα, διαβιβαστες, συνθεσεις του ιου της ανθρωπινης ανοσοανεπαρκειας, και μεθοδοι χρησης τους | |
| MX2019004810A (es) | Ácidos ribonucleicos mensajeros para aumentar respuestas inmunes y métodos para usarlos. | |
| CY1122214T1 (el) | Αντισωματα ειδικα για ton fcrn | |
| CL2019000392A1 (es) | Métodos para detectar aav. | |
| MD4655B1 (ro) | Virusurile bolii de Newcastle şi utilizarea acestora | |
| CY1120740T1 (el) | Βελτιωμενα ευλογοϊικα εμβολια | |
| WO2015109124A3 (en) | Immunomodulatory agents | |
| BR112016000303A2 (pt) | partícula tipo viral que compreende antígeno pd-1 ou antígeno ligante pd-1, molécula de ácido nucleico isolada, vetor, composição farmacêutica, uso dos mesmos, e kit | |
| TN2018000152A1 (en) | Nucleic acid vaccines for varicella zoster virus (vzv) | |
| EP3490583A4 (en) | ONCOLYTIC HERPES SIMPLEX VIRUS VECTORS EXPRESSING IMMUNE SYSTEM-STIMULATING MOLECULES | |
| EA201891022A1 (ru) | Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела | |
| EP3316959C0 (en) | SYSTEM FOR INTER-FREQUENCY COUPLING AND NEUROMODULATION DETECTION | |
| TN2016000076A1 (en) | Gitr antigen binding proteins. | |
| BR112017023131A2 (pt) | anticorpos anti- fcrn | |
| MX2019007921A (es) | Nuevos agentes de union a ha. | |
| IL263979B1 (en) | Enveloped virus resistant to complement inactivation for the treatment of cancer | |
| MX2015016304A (es) | Proteinas de union al antigeno del receptor de oncostatina m. | |
| IL281730A (en) | Combinations of oncolytic vaccinia virus and immune checkpoint inhibitors for treating cancer, and pharmaceutical compositions comprising such combinations | |
| MX2017011991A (es) | Terapia virica con una combinacion de anticuerpos. | |
| EA201691120A1 (ru) | Векторные композиции и способы индукции усиленного иммунного ответа с использованием векторов поксвируса | |
| PH12016501444A1 (en) | Antibodies against f glycoprotein of hendra and nipah viruses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG4A | Patent for invention issued |